Jul 29
|
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
|
Jul 12
|
When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?
|
May 12
|
Earnings Update: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported And Analysts Are Boosting Their Estimates
|
May 10
|
Tarsus Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
|
May 9
|
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
|
May 9
|
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript
|
May 9
|
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
|
May 8
|
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
|
May 8
|
Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
|
May 6
|
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
|
May 1
|
Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
|
Apr 23
|
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
|
Apr 19
|
Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%
|
Apr 8
|
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
|
Apr 4
|
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
|
Apr 1
|
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
|
Mar 6
|
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
|
Mar 5
|
Tarsus to Participate at Upcoming Investor Conferences
|
Mar 5
|
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
|
Dec 11
|
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
|